Icosapent Ethyl Effects on Fatty Acid Profiles in Statin-Treated Patients With High Triglycerides: The Randomized, Placebo-controlled ANCHOR Study

Cardiology and Therapy
Christie M BallantyneRebecca A Juliano

Abstract

Fatty acid content in plasma and red blood cells (RBCs) may provide insight into potential physiologic benefits of omega-3 fatty acids. Icosapent ethyl is a pure prescription form of eicosapentaenoic acid (EPA) ethyl ester approved by the US Food and Drug Administration at a dose of 4 g/day as an adjunct to diet to reduce triglyceride levels in adults with severe (≥ 500 mg/dl) hypertriglyceridemia. This was a prespecified exploratory subset analysis of the ANCHOR study, which randomized 702 statin-treated patients at increased cardiovascular risk with triglycerides 200-499 mg/dl and controlled low-density lipoprotein cholesterol (40-99 mg/dl). This analysis examined effects of icosapent ethyl 4 g/day versus placebo on fatty acid levels in plasma and RBCs using a gas chromatograph assay method with flame ionization detector. In plasma, treatment with icosapent ethyl 4 g/day resulted in significant increases versus placebo in the mean concentrations of EPA (+ 635%; P < 0.0001) and its metabolite, docosapentaenoic acid n-3 (+ 143%; P < 0.0001) with no significant change in docosahexaenoic acid. Treatment with icosapent ethyl 4 g/day versus placebo also resulted in significant decreases in the omega-6 fatty acids linoleic acid (- 2...Continue Reading

References

Nov 1, 1995·JAMA : the Journal of the American Medical Association·D S SiscovickL H Kushi
Jan 5, 2000·The American Journal of Clinical Nutrition·M J JamesL G Cleland
Jun 23, 2004·Preventive Medicine·William S Harris, Clemens Von Schacky
Jul 18, 2006·The American Journal of Clinical Nutrition·Philip C Calder
Sep 19, 2006·Cardiovascular Research·Clemens von Schacky, William S Harris
Apr 3, 2007·Lancet·Mitsuhiro YokoyamaUNKNOWN Japan EPA lipid intervention study (JELIS) Investigators
Sep 8, 2009·Clinical Biochemistry·William S Harris, Rachael M Thomas
Nov 26, 2010·Journal of Atherosclerosis and Thrombosis·Hiroshige ItakuraUNKNOWN JELIS Investigators
Nov 5, 2011·Journal of the American College of Cardiology·Dariush Mozaffarian, Jason H Y Wu
Oct 10, 2012·International Journal of Cardiology·William S HarrisJohn A Spertus
Jan 18, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Harold E BaysParesh N Soni
Sep 21, 2013·Journal of Atherosclerosis and Thrombosis·Haruo Ohnishi, Yasushi Saito
May 4, 2016·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jonathan Fialkow
Jul 16, 2016·Prostaglandins & Other Lipid Mediators·Harold E BaysSephy Philip
Nov 13, 2018·The New England Journal of Medicine·John F Keaney, Clifford J Rosen
Nov 13, 2018·The New England Journal of Medicine·Deepak L BhattUNKNOWN REDUCE-IT Investigators

❮ Previous
Next ❯

Citations

Nov 5, 2019·The Journal of Clinical Endocrinology and Metabolism·Huaizhu WuChristie M Ballantyne
Oct 17, 2020·European Heart Journal Supplements : Journal of the European Society of Cardiology·Timothy D O'ConnellGregory C Shearer

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01492361

Software Mentioned

JELIS
ANCHOR
REDUCE
IT

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.